Aureus Pharma and Collaborators Awarded Eureka Funding
News May 16, 2006
Aureus Pharma and ChemAxon have announced that they have been awarded a European Eureka project along with pharmaceutical partner sanofi-aventis and academic partner Budapest University of Technology and Economics.
The goal of the project KnowTox® is to build a knowledge base related to hepatotoxicity as well as related predictive tools to extend the value of the system.
Drug-induced hepatotoxicity or liver damage/disease is a major concern during the drug development process.
Having access to a knowledge database containing detailed biological and chemical data and associated analysis applications will lead to better use of available knowledge during drug development.
In this project, Aureus Pharma brings its expertise in building chemical biology knowledge databases, sanofi-aventis provides toxicological experts from the pharma industry to validate the products and ChemAxon, a software solution provider and Budapest University of Technology and Economics with their expertise in chemical reaction modeling will extend their software tools to deal with reactions and substrates involved in the metabolism of compounds and also develop predictive tools for hepatoxicity.
"We are pleased Aureus Pharma can bring to this partnership its expertise to build a knowledge database related to hepatoxicity," said Dr. François Petitet, Director of Life Sciences at Aureus Pharma.
"This will allow researchers access to previous failures and pertinent toxic alerts which will limit failure during the drug discovery process."
Dr. Miklos Vargyas, Chief Science Officer at ChemAxon added, "This knowledge can be used in building computational models capable of predicting metabolites and their hepatoxicity, so extending the scope of insilico approaches"
It is expected that the KnowTox Knowledge database and predictive tools will be commercially available upon completion of the project.
In a new study published in Cell Stem Cell, a team of researchers have demonstrated, using fat cells derived from human stem cells, that individual genetic variation can be used to predict whether the TZD rosiglitazone will produce the unwanted side effect of increasing cholesterol levels in certain individuals.READ MORE